Previous 10 | Next 10 |
NEW YORK and BASEL, Switzerland , Jan. 2, 2019 /PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy , Founder and Chief Executive Officer of Roivant, will present an overview of the business as well as new data updates from private companies in the Roivant family ...
NEW YORK, Dec. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Canopy Growth Corporation (NYSE:CGC), ArQule, Inc. (NASDAQ:ARQL), Mone...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signi...
Proteostasis Therapeutics (NYSE: PTI ) +18% on deal with Genentech. More news on: Proteostasis Therapeutics, Axovant Sciences, Evofem Biosciences, Inc., Stocks on the move, , Read more ...
Taiwan Liposome ( TLC ) initiated with Buy rating at Janney Montgomery. More news on: Taiwan Liposome Co., Argenx SE, Axovant Sciences, Healthcare stocks news, Stocks on the move, , Read more ...
Primary efficacy endpoint assessed by sleep laboratory video assessment was not met Axovant is discontinuing clinical development of nelotanserin BASEL, Switzerland, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) a clinical-stage gene therapy company, toda...
Axovant Sciences (NASDAQ: AXON ): Q2 GAAP EPS of -$0.28 beats by $0.05 . More news on: Axovant Sciences, Earnings news and commentary, Healthcare stocks news, , Read more ...
First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s disease Expanded pipeline of gene therapies with in-licensing of AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy (OPMD) and collaboration agreement for five a...
Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient ...
BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the Jefferies Gene Therapy Summit 2018 on September 27, 2018 at 9:45 a.m. ET. Additionally, Dr. Cheru...
News, Short Squeeze, Breakout and More Instantly...
Axon Appoints Isaiah Fields as Chief Legal Officer PR Newswire SCOTTSDALE, Ariz. , July 13, 2022 /PRNewswire/ -- Axon (NASDAQ: AXON), the global leader in connected public safety technologies, today announced the appointment of Isaiah Fields t...
The S&P 500 has fallen 22% from its all-time high, putting the benchmark index in a bear market. Losses of that magnitude can leave even experienced investors feeling rattled, but the worst mistake you can make is allowing yourself to get scared out of high-quality stocks. The durat...
Apple has the kind of brand authority most companies will never achieve, and it has used that competitive advantage to build a very sticky business . Specifically, by pairing first-party hardware with software and services, Apple benefits from recurring revenue and high switching co...